Cargando…

Labeling T Cells to Track Immune Response to Immunotherapy in Glioblastoma

While the advent of immunotherapy has revolutionized cancer treatment, its use in the treatment of glioblastoma (GBM) has been less successful. Most studies using immunotherapy in GBM have been negative and the reasons for this are still being studied. In clinical practice, interpreting response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhee, John Y., Ghannam, Jack Y., Choi, Bryan D., Gerstner, Elizabeth R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959194/ https://www.ncbi.nlm.nih.gov/pubmed/36828374 http://dx.doi.org/10.3390/tomography9010022

Ejemplares similares

Metabolic Barriers to Glioblastoma Immunotherapy
por: Choudhary, Nikita, et al.
Publicado: (2023)

The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma
por: Ghosh, Mitrajit, et al.
Publicado: (2022)

Clinical scale labeling of T cell immunotherapy for MRI cell tracking
por: Helfer, Brooke M, et al.
Publicado: (2015)

Immune cell labelling and tracking: implications for adoptive cell transfer therapies
por: Galli, Filippo, et al.
Publicado: (2021)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022)

Natural killer cell immunotherapy in glioblastoma
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Biomarkers for immunotherapy for treatment of glioblastoma
por: Lynes, John P, et al.
Publicado: (2020)

Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas
por: Chawla, Sanjeev, et al.
Publicado: (2021)

Sexual dimorphism of the immune system predicts clinical outcomes in glioblastoma immunotherapy: A systematic review and meta-analysis
por: Shireman, Jack M, et al.
Publicado: (2022)

The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy
por: Yeo, Erica C. F., et al.
Publicado: (2021)

Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
por: Park, Jang Hyun, et al.
Publicado: (2022)

Virus-Based Immunotherapy of Glioblastoma
por: Martikainen, Miika, et al.
Publicado: (2019)

Emerging Biomarkers for Immunotherapy in Glioblastoma
por: Mensali, Nadia, et al.
Publicado: (2022)

Advances in Immunotherapy for Adult Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2021)

Next Steps for Immunotherapy in Glioblastoma
por: Cao, Toni Q., et al.
Publicado: (2022)

A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
por: Srivastava, Siddhartha, et al.
Publicado: (2019)

Glioblastoma Immune Landscape and the Potential of New Immunotherapies
por: Daubon, Thomas, et al.
Publicado: (2020)

Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
por: Arnesen, Victoria Smith, et al.
Publicado: (2021)

Natural Killer Cell-Based Immunotherapy against Glioblastoma
por: Morimoto, Takayuki, et al.
Publicado: (2023)

Advances in immunotherapy for the treatment of glioblastoma
por: Tivnan, Amanda, et al.
Publicado: (2016)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
por: Schmidts, Andrea, et al.
Publicado: (2022)

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
por: Pearson, Joshua R. D., et al.
Publicado: (2020)

Immunotherapy in Glioblastoma: A Clinical Perspective
por: Desbaillets, Nicolas, et al.
Publicado: (2021)

Immunotherapy for glioblastoma: the promise of combination strategies
por: Bausart, Mathilde, et al.
Publicado: (2022)

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
por: Liu, Xudong, et al.
Publicado: (2023)

Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
por: Singh, Kirit, et al.
Publicado: (2022)

Immunocompetent murine models for the study of glioblastoma immunotherapy
por: Oh, Taemin, et al.
Publicado: (2014)

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
por: ISHIKAWA, Eiichi, et al.
Publicado: (2017)

Commercial Nanoparticles for Stem Cell Labeling and Tracking
por: Wang, Yaqi, et al.
Publicado: (2013)

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
por: Yang, Liu, et al.
Publicado: (2015)

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
por: Gardam, Bryan, et al.
Publicado: (2023)

Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy
por: Feng, Peng, et al.
Publicado: (2022)

Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
por: Conniot, João, et al.
Publicado: (2014)

Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
por: Smith, Peter Lawrence, et al.
Publicado: (2021)

Overview of Cellular Immunotherapy for Patients with Glioblastoma
por: Vauleon, Elodie, et al.
Publicado: (2010)

Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
por: Ahn, Jaehyun, et al.
Publicado: (2022)

Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma
por: Jin, Ketao, et al.
Publicado: (2021)

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives
por: Sener, Ugur, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_64f13v9o79h0jtbdgmf1kkducl